- Home
- NKTR vs AVIR Comparison
NKTR vs AVIR Comparison
Compare NKTR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- AVIR
- Stock Information
- Founded
- NKTR 1990
- AVIR 2012
- Country
- NKTR United States
- AVIR United States
- Employees
- NKTR N/A
- AVIR N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- NKTR Health Care
- AVIR Health Care
- Exchange
- NKTR Nasdaq
- AVIR Nasdaq
- Market Cap
- NKTR 247.9M
- AVIR 251.7M
- IPO Year
- NKTR 1994
- AVIR 2020
- Fundamental
- Price
- NKTR $0.93
- AVIR $3.09
- Analyst Decision
- NKTR Strong Buy
- AVIR Hold
- Analyst Count
- NKTR 5
- AVIR 1
- Target Price
- NKTR $4.50
- AVIR $6.88
- AVG Volume (30 Days)
- NKTR 3.0M
- AVIR 329.3K
- Earning Date
- NKTR 03-07-2025
- AVIR 03-03-2025
- Dividend Yield
- NKTR N/A
- AVIR N/A
- EPS Growth
- NKTR N/A
- AVIR N/A
- EPS
- NKTR N/A
- AVIR N/A
- Revenue
- NKTR $93,137,000.00
- AVIR N/A
- Revenue This Year
- NKTR $12.15
- AVIR N/A
- Revenue Next Year
- NKTR N/A
- AVIR N/A
- P/E Ratio
- NKTR N/A
- AVIR N/A
- Revenue Growth
- NKTR 5.53
- AVIR N/A
- 52 Week Low
- NKTR $0.63
- AVIR $2.75
- 52 Week High
- NKTR $1.93
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- NKTR 53.83
- AVIR 48.26
- Support Level
- NKTR $0.92
- AVIR $3.04
- Resistance Level
- NKTR $1.08
- AVIR $3.25
- Average True Range (ATR)
- NKTR 0.09
- AVIR 0.13
- MACD
- NKTR 0.03
- AVIR 0.01
- Stochastic Oscillator
- NKTR 65.63
- AVIR 54.29
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).